The BAP18/CTCF/NURF Complex Contributes to Modulation of Enhancer RNAs and Endocrine Resistance in Breast Cancer

Ge Sun,Yuntao Wei,Baosheng Zhou,Tianyu Tang,Manlin Wang,Ruina Luan,Yu Bai,Hao Li,Shan Wang,Chunyu Wang,Shengli Wang,Kai Zeng,Renlong Zou,Lin Lin,Wei Liu,Qiang Zhang,Yue Zhao
DOI: https://doi.org/10.2139/ssrn.4076337
2022-01-01
SSRN Electronic Journal
Abstract:Endocrine therapy is the common therapeutic strategy for estrogen receptor alpha (ERα)-positive breast cancer, but intrinsic endocrine resistance leads a significant challenge. CTCF as a transcription factor is essential for enhancer-promoter looping to be involved in hyperactivation of ERα-associated enhancers, however, the molecular mechanism underlying the modulation of CTCF in transcription of enhancers is still elusive. Here, we have identified BAP18 as a critical enhancer modulator has a global recruitment on gene enhancer combining with CTCF. Consistently, ERα-related enhancer transactivation is positively correlated with increasing BAP18 enrichment. BAP18 interacts with SMARCA1, another NURF complex subunit, participating in modulating CTCF recruitment on ERα-related enhancers. Interestingly, BAP18 globally facilitated chromatin accessibility of enhancer regions, especially within CTCF binding sites, thereby increasing targeted enhancer-promoter looping (E-P looping) via CTCF recruitment. The results demonstrate that BAP18 depletion increase the sensitivity of anti-estrogen and anti-enhancer treatment in multiple aromatase inhibitor-nonresponse models. Collectively, our study suggest that BAP18 coordinates with CTCF in enlarging the transactivation of ERα-related enhancers, providing a better understanding the function of BAP18/CTCF/NURF coupling chromatin remodeling and E-P looping in enhancement of enhancer transcription.
What problem does this paper attempt to address?